Biocon Limited (BIOCON.NS) fair value

ACCE thesis

Biocon makes generic and biosimilar versions of large-molecule drugs, including insulin, monoclonal antibodies such as trastuzumab and bevacizumab, and oral small-molecule generics, sold across regulated US and European markets plus emerging markets. Its edge is a manufacturing and regulatory footprint that few Indian peers have replicated for complex biologics, which takes years and many filings to build. Revenue is growing about 10% a year, and the forward P/E of 30.2 sits well below the trailing 97.7, which suggests the market is pricing a sharp earnings recovery rather than the current base. The operating margin of 6.9% against a 61.2% gross margin shows how much of the gross profit is absorbed by R&D and SG&A, so the margin story is the central question. The stock merits a deeper look if you want exposure to the biosimilar cycle and can underwrite margin expansion from here.